Search

everythinglearnresearchcommunity

for

Search:↓

Methotrexate effectively controls eye inflammation in Japanese patients with non-infectious uveitis but requires careful monitoring for side effects.

Applying the anti-cancer drug Bortezomib to skin can promote hair growth and increase hair proteins through the GATA-3 factor.

A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

The NUDT15 gene variant causes severe side effects from azathioprine in some Indian patients.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

Compound N4 effectively kills breast cancer cells and compounds N2 and N3 have strong antibacterial and antifungal properties.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.

A3B5 can reduce skin pigmentation and slow melanoma growth.

Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

Skin side effects from melanoma immunotherapy are common and may indicate better survival.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.

Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

The formulated gel is a promising treatment for alopecia areata.

Immunotherapies for non-small cell lung cancer show promise in improving treatment and reducing side effects.